Scholars Central

ArticlePublished 17 May 2024

Effectiveness of Rituximab in Conjunction with Cyclosporine in Managing Refractory Idiopathic Thrombocytopenia

Authors: Xiangjun Fu, Can Meng, Li Guo, Lie Lin

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

To evaluate the effectiveness of rituximab in conjunction with cyclosporine in managing refractory idiopathic thrombocytopenia. A retrospective analysis was performed on 210 adult individuals diagnosed with refractory idiopathic thrombocytopenia upon admission to our medical facility in 2022. Subsequently, they were categorized into distinct treatment cohorts: 98 individuals in the control group and 112 individuals in the observation group. Standard treatment protocols were administered to the control group, while the observation group received supplementary low-dose rituximab alongside the standard treatment regimen followed by the control group. The evaluation encompassed pre- and post-treatment efficacy, fluctuations in cluster of differentiate 20+ expression and platelet count, levels of interleukin-18 and tumor necrosis factor alpha in patient serum, adverse reactions, and recurrence of thrombocytopenia. 4 w post-treatment, the observation group yielded remarkably superior outcomes, with a total effective rate of 92.86 %, compared to the control group’s rate of 77.55 % (p 0.05). The recurrence rate of thrombocytopenic purpura in the observation group was notably reduced as opposed to the control group, a difference that proved to be substantially significant (p<0.05). The concurrent usage of rituximab and cyclosporine in managing refractory idiopathic thrombocytopenic purpura exhibits marked clinical effectiveness and a commendable safety profile. The integrated treatment strategy holds potential benefits for symptom amelioration, enhancement of platelet levels, and the prevention of disease relapse, indicative of favorable attributes.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Indian Journal of Pharmaceutical Sciences.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalIndian Journal of Pharmaceutical Sciences
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Xiangjun Fu”
  • BylineArticles whose byline prints “Can Meng”
  • BylineArticles whose byline prints “Li Guo”
  • BylineArticles whose byline prints “Lie Lin”